leisure time -WSS

leisure time

author：fashion 2025-09-30 21:27:12 - browse：39137

AbbVie announced Tuesday that CEO Richard Gonzalez, who has managed the company’s ascent since it was spun off from the device maker Abbott Laboratories in 2013, will step down in July. Gonzalez had previously said he would depart when AbbVie had a plan in place to move on from its best-selling drug, Humira, which is now facing competition from cheaper biosimilars.

He will be replaced by Chief Operating Officer Robert Michael, who, like Gonzalez, is a longtime AbbVie executive. Gonzalez, 70, will become executive chairman of the board of directors.

Gonzalez should be a sobering reminder to the drug industry’s critics of how resilient a CEO’s reputation can be. Because while he has been a subject of nearly constant criticism for AbbVie’s handling of Humira and the patents protecting it, investors are likely to remember him fondly.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The drug industry has found itself all alone in Washington

focus

WSS

Cholera vaccine supply gets boost as demand surges globally

H5N1 bird flu found in pasteurized milk: what we know

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Change Healthcare cyberattack prompts Medicare loan program

Sen. Paul opposes bill to ban Chinese biotechs

Diversity in clinical trials starts with building trust, experts say

focus

leisure time

Wikipedia

After affirmative action ruling, medical educators look to 'holistic review'

Bird flu outbreak in cows is latest avian flu curveball

Drug repurposing or repositioning? The language matters

Cell therapy fails to slow type 1 diabetes, but safety is established

State Dept. review finds Biden bears some blame for Afghanistan failures

Dogs on Prozac: What pet anti

Malaria cases in Florida and Texas: Here’s what you need to know

MultiPlan and major insurers sued for alleged medical price

Supreme Court strikes down use of affirmative action

IVF, abortion rights issues kick off Biden’s State of the Union

focus

Change Healthcare cyberattack prompts Medicare loan program

Diversity in clinical trials starts with building trust, experts say

Health care needs a new profession: neuroimaging counseling

Amylyx ALS drug fails large clinical trial

MultiPlan and major insurers sued for alleged medical price

The problem with charging patients to message their doctors

leisure time

focus

focus

focus